NASDAQ · Biotechnology

Intellia Therapeutics, Inc. (NTLA) Stock

$11.42 +0.71% NASDAQ: NTLA Healthcare

Valuation

MetricValue
Price$11.42
Market Cap$1.60B
P/E Ratio-3.65
P/B Ratio2.25
P/S Ratio28.79
EPS (TTM)$-3.81
52-Week High$28.25
52-Week Low$7.95
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-57.79%
ROA-46.66%
ROCE-54.45%
Gross Margin-648.53%
Operating Margin-648.53%
Net Margin-672.16%
Debt/Equity0.10
Current Ratio5.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$33.0M$52.0M$36.0M$58.0M$68.0M
Operating Profit$-268.0M$-458.0M$-515.0M$-534.0M$-441.0M
Net Profit$-268.0M$-474.0M$-481.0M$-519.0M$-413.0M
EPS$-3.78$-6.16$-5.42$-5.25$-3.81
Op Margin-810.4%-879.0%-1420.5%-923.1%-651.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.3B$1.5B$1.3B$1.2B$842.0M
Total Liabilities$254.0M$285.0M$251.0M$319.0M$171.0M
Cash$123.0M$524.0M$227.0M$189.0M$155.0M
Borrowings$74.0M$131.0M$115.0M$210.0M$93.0M

Latest News

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success Simply Wall St. · Jul 9, 2026 NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? Zacks · Jul 9, 2026 Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns Simply Wall St. · Jul 9, 2026 Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears Barchart · Jul 8, 2026 A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics Motley Fool · Jul 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-225.0M$-333.0M$-394.0M$-349.0M$-349.0M
Investing Cash Flow$-564.0M$102.0M$-45.0M$120.0M$120.0M
Financing Cash Flow$43.0M$17.0M$11.0M$9.0M$54.0M
Net Cash Flow$-39.0M$410.0M$-295.0M$-38.0M$-38.0M
Free Cash Flow$-238.0M$-392.0M$-408.0M$-355.0M$-355.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.10
EV / EBITDA-4.30
FCF Yield-27.21%
Quick Ratio6.65
Interest Coverage—
Return 1Y-22.05%
Return 3Y-73.52%
Return 5Y-90.37%

Ownership

Insiders Held3.88%
Institutions Held76.79%
Institutions Float Held79.89%
Institutional HolderSharesReport Date
ARK Investment Management, LLC14,509,2472026-03-31
Blackrock Inc.12,155,8062026-03-31
State Street Corporation6,922,6762026-03-31
Vanguard Portfolio Management LLC6,223,3252026-03-31
Shaw D.E. & Co., Inc.5,728,1772026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BEAMBeam Therapeutics Inc. $23.47 -5.10% -29.88 $2.42B 0.00%
CRBUCaribou Biosciences, Inc. $0.47 +1.12% -1.13 $50.38M 0.00%
CRSPCRISPR Therapeutics AG $49.25 -4.41% -11.62 $4.76B 0.00%
EDITEditas Medicine, Inc. $2.35 -3.69% -3.50 $360.91M 0.00%
MGTXMeiraGTx Holdings plc $9.28 -6.17% 17.43 $891.28M 0.00%

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is led by CEO John Leonard, employs 403 people, headquartered in US, publicly traded since 2016.

Intellia Therapeutics, Inc. (NTLA) stock trades at $11.42 with a market capitalization of $1.60B. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.65, reflecting a net loss over the last twelve months, price-to-book of 2.25, price-to-sales of 28.79. Over the past 52 weeks the stock has ranged between $7.95 and $28.25, and currently trades 59.6% below its 52-week high.

On profitability, Intellia Therapeutics, Inc. generates a return on equity (ROE) of -57.79% (negative, reflecting a net loss), return on capital employed of -54.45%, an operating margin of -648.53%, a net profit margin of -672.16%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.